logo
NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

CTV News12 hours ago
This diagram provided by NASA/JPL-Caltech shows the trajectory of interstellar comet 3I/ATLAS as it passes through the solar system. (NASA/JPL-Caltech via AP)
CAPE CANAVERAL, Fla. — NASA has discovered an interstellar comet that's wandered into our backyard.
The space agency spotted the quick-moving object with the sky-surveying Atlas telescope in Chile earlier this week, and confirmed it was a comet from another star system. It's officially the third known interstellar object to pass through our solar system and poses no threat to Earth.
The newest visitor is 416 million miles (670 million kilometres) from the sun, out near Jupiter. NASA said the comet will make its closest approach to the sun in October, scooting between the orbits of Mars and Earth — but closer to the red planet than us at a safe 150 million miles (240 million kilometres) away.
Astronomers around the world are monitoring the comet — an icy snowball officially designated 3I/Atlas — to determine its size and shape. It should be visible by telescopes through September, before it gets too close to the sun, and reappear in December on the other side of the sun.
The first interstellar visitor observed from Earth was Oumuamua, Hawaiian for scout, in honor of the observatory in Hawaii that discovered it in 2017. Classified at first as an asteroid, the elongated Oumuamua has since showed signs of being a comet.
The second object confirmed to have strayed from another star system into our own —— 21/Borisov — was discovered in 2019 by a Crimean amateur astronomer with that name. It, too, is believed to be a comet.
___
Marcia Dunn, The Associated Press
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time4 hours ago

  • Globe and Mail

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'
Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'

Globe and Mail

time6 hours ago

  • Globe and Mail

Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors'

Dr. Michael Rimlawi Announces National Scholarship Opportunity for Aspiring Physicians Through the 'Dr. Michael Rimlawi Scholarship for Future Doctors' Dallas, Texas - The Dr. Michael Rimlawi Scholarship for Future Doctors is now open for applications, offering a meaningful academic opportunity to undergraduate students across the United States who are committed to pursuing a career in medicine. Spearheaded by renowned spine surgeon Dr. Michael Rimlawi, this scholarship reflects a deep commitment to supporting the next generation of healthcare leaders who are ready to make a difference in the field of medicine. The scholarship is designed for undergraduate students enrolled at accredited colleges or universities who have set their sights on a future in healthcare. In line with Dr. Michael Rimlawi's dedication to innovation and mentorship in the medical field, the program encourages thoughtful reflection on personal inspiration and the impact future doctors wish to have in the profession. To be considered, applicants must submit an original essay between 500 and 750 words responding to the prompt: 'What inspired you to pursue a career in medicine, and how do you hope to make a difference in the field?' Essays will be evaluated on clarity, originality, and depth of insight. The deadline for application submissions is January 15, 2026, and the scholarship recipient will be announced on February 15, 2026. Dr. Michael Rimlawi, who is widely respected for his pioneering contributions in minimally invasive spine surgery, brings both clinical excellence and visionary leadership to the scholarship initiative. As a physician who has led advancements in micro-endoscopic techniques and was the first in the nation to perform the Globus Minimally Invasive XLIF procedure, Dr. Rimlawi understands the transformative impact of dedication and continuous learning in medicine. Through this scholarship, Dr. Michael Rimlawi aims to help lessen the financial burden for students who demonstrate not only academic determination but also a clear vision for how they intend to shape the healthcare system in meaningful ways. The scholarship is not limited by geographic region and is open to qualified undergraduate students throughout the United States. 'Mentoring future doctors has always been a personal mission,' says Dr. Michael Rimlawi, who has long advocated for educational support as a means to uplift future medical professionals. By launching this scholarship, Dr. Michael Rimlawi seeks to provide more than financial aid—he offers recognition and encouragement to students committed to advancing patient-centered care. The Dr. Michael Rimlawi Scholarship for Future Doctors continues to grow as an extension of Dr. Rimlawi's broader mission: to foster innovation, compassion, and progress within the healthcare system by investing in students who will become the physicians of tomorrow. Applicants interested in this opportunity are encouraged to visit the official website to review the full eligibility criteria and submit their essays through the application portal. For more details or to apply, visit below. Media Contact Company Name: Dr. Michael Rimlawi Scholarship Contact Person: Dr. Michael Rimlawi Email: Send Email City: Dallas State: Texas Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store